<p>Avanos Medical, Inc.（紐約證券交易所代碼：AVNS - 獲取免費報告）在週三的交易中出現了異常強勁的交易量。當天交易了約 1,089,603 股，較前一交易日的 903,790 股增加了 21%。該股票最後交易價格為 24.6050 美元，之前收盤價為 24.63 美元。</p>
<p>獲取 <strong>Avanos Medical</strong> 的提醒：</p>
<h2>更多 Avanos Medical 新聞</h2>
<p>以下是本週影響 Avanos Medical 的關鍵新聞：</p>
<ul>
<li>積極情緒：交易：Avanos 同意以每股 25.00 美元的現金被美國工業合作伙伴的附屬公司收購，估值約為 12.7 億美元——這是一項約 72% 的溢價，為公眾股東提供了即時且確定的價值。Avanos 股票因 12.7 億美元的 AIP 收購交易而大幅上漲，溢價 72%。</li>
<li>積極情緒：運營信號：Avanos 報告第四季度業績超出預期（每股收益 0.29 美元，預期 0.24 美元；收入超出預期），並保留機構持有者，這支持了業務在戰略交易背後基本面改善的敍述。Avanos Medical 發佈第四季度業績超出預期，機構投資者如 Armistice Capital 在非阿片類止痛設備領域持有頭寸。</li>
<li>中性情緒：市場覆蓋：媒體跟蹤了該股票歷史性的日內飆升，並總結了交易條款和時機；這只是信息性內容，但並未改變交易經濟。AVNS 股票記錄歷史性日內飆升——關於美國工業合作伙伴的收購交易你需要知道的一切。</li>
<li>消極情緒：法律/關閉風險：多家股東律師事務所已啓動調查和警報，聲稱與此次出售相關的潛在不公平價格或信託責任違反；訴訟或挑戰可能會延遲交易完成，增加成本或施壓董事會尋求更高的出價。$HAREHOLDER ALERT: M-A 集體訴訟事務所宣佈對 Avanos Medical, Inc.（紐約證券交易所代碼：AVNS）進行調查。</li>
</ul>
<h2>分析師評級變動</h2>
<p>幾位研究分析師最近對該股票發表了看法。Zacks Research 在 1 月 26 日的研究報告中將 Avanos Medical 的股票評級從 “強烈賣出” 上調至 “持有”。Weiss Ratings 在 12 月 22 日的研究報告中重申了對 Avanos Medical 股票的 “賣出（d-）” 評級。最後，Wall Street Zen 在 3 月 28 日的研究報告中將 Avanos Medical 的股票評級從 “持有” 上調至 “買入”。一位研究分析師對該股票給予了 “持有” 評級，另一位則給予了 “賣出” 評級。根據 MarketBeat，該公司的共識評級為 “減持”。</p>
<p><strong>獲取我們最新的 AVNS 股票報告</strong></p>
<h2>Avanos Medical 股票表現</h2>
<p>該公司的速動比率為 1.26，流動比率為 2.15，債務與股本比率為 0.12。該公司的 50 日移動平均線為 14.27 美元，200 日移動平均線為 12.61 美元。該公司的市值為 11.4 億美元，市盈率為-15.58，貝塔值為 1.05。</p>
<p>Avanos Medical（紐約證券交易所代碼：AVNS - 獲取免費報告）最後一次發佈季度財報是在 2 月 24 日。該公司報告第四季度每股收益為 0.29 美元，超出共識預期的 0.24 美元，超出 0.05 美元。Avanos Medical 的淨利潤率為-10.40%，股本回報率為 5.47%。該公司第四季度的收入為 1.809 億美元，超過分析師預期的 1.747 億美元。在去年同期，該公司每股收益為 0.43 美元。Avanos Medical 本季度的收入較去年同期增長了 0.7%。Avanos Medical 已將 2026 財年的指導目標設定為每股收益 0.900-1.100。股票分析師預計 Avanos Medical, Inc. 本財年將發佈每股收益 1.32 美元。</p>
<h2>機構資金流入和流出</h2>
<p>一些機構投資者和對沖基金最近買入和賣出了 AVNS 的股票。AQR Capital Management LLC 在第一季度將其在 Avanos Medical 的持倉增加了 46.4%。AQR Capital Management LLC 目前擁有 192,864 股該公司的股票，價值 2,700,000 美元，此前在上個季度增持了 61,095 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第一季度將其在 Avanos Medical 的持倉增加了 4.3%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 目前擁有 26,955 股該公司的股票，價值 386,000 美元，此前在上個季度增持了 1,121 股。Millennium Management LLC 在第一季度將其在 Avanos Medical 的持倉增加了 508.3%。Millennium Management LLC 目前擁有 547,740 股該公司的股票，價值 7,849,000 美元，此前在上個季度增持了 457,703 股。Empowered Funds LLC 在第一季度將其在 Avanos Medical 的持倉增加了 5.4%。Empowered Funds LLC 目前擁有 162,182 股該公司的股票，價值 2,324,000 美元，此前在上個季度增持了 8,348 股。最後，UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC 在第一季度將其在 Avanos Medical 的持倉增加了 17.1%。UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC 目前擁有 140,810 股該公司的股票，價值 2,018,000 美元，此前在上個季度增持了 20,541 股。95.17% 的股票目前由機構投資者持有。</p>
<h2>Avanos Medical 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Avanos Medical 是一家全球醫療技術公司，開發和銷售廣泛的醫療設備組合，旨在改善醫院、門診和後期護理環境中的患者結果。該公司的產品專注於三個核心治療領域——疼痛管理、腸內餵養和呼吸護理——旨在幫助臨牀醫生管理術後疼痛、提供營養支持並協助各種急性和慢性病症患者的呼吸。</p>
<p>在疼痛管理領域，Avanos 提供非阿片類藥物輸送系統和冷凍鎮痛設備，包括可移動輸液泵和冷卻射頻消融平台。</p>
<h2>推薦故事</h2>
<ul>
<li>五隻我們認為比 Avanos Medical 更好的股票</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Avanos Medical 嗎？</h2>
<p>在考慮 Avanos Medical 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Avanos Medical 並不在名單上。</p>
<p>雖然 Avanos Medical 目前在分析師中被評為減持，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

AVNS

<p>Avanos Medical（紐約證券交易所代碼：AVNS）經歷了顯著的交易量增加，交易量達到 1,089,603 股，比前一交易日增長 21%。該股票目前價格為 24.6050 美元。公司已同意以每股 25.00 美元的價格被美國工業合夥人收購，溢價達到 72%。儘管盈利報告積極，但關於此次出售的法律調查可能帶來風險。分析師的評級意見不一，普遍評級為 “減持”。機構投資者對該股票表現出更高的興趣，反映出對其基本面的積極展望</p>

<p>Shares of Avanos Medical, Inc. (NYSE:AVNS - Get Free Report) saw unusually-strong trading volume on Wednesday . Approximately 1,089,603 shares were traded during trading, an increase of 21% from the previous session's volume of 903,790 shares.The stock last traded at $24.6050 and had previously closed at $24.63.</p>
<div class="lb-trans"><p>Avanos Medical, Inc.（紐約證券交易所代碼：AVNS - 獲取免費報告）在週三的交易中出現了異常強勁的交易量。當天交易了約 1,089,603 股，較前一交易日的 903,790 股增加了 21%。該股票最後交易價格為 24.6050 美元，之前收盤價為 24.63 美元。</p>
</div><p>Get <strong>Avanos Medical</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Avanos Medical</strong> 的提醒：</p>
</div><h2>More Avanos Medical News</h2>
<div class="lb-trans"><h2>更多 Avanos Medical 新聞</h2>
</div><p>Here are the key news stories impacting Avanos Medical this week:</p>
<div class="lb-trans"><p>以下是本週影響 Avanos Medical 的關鍵新聞：</p>
</div><ul>
<li>Positive Sentiment: Deal: Avanos agreed to be acquired by affiliates of American Industrial Partners for $25.00 per share in cash, valuing the company at ~ $1.27B — a ~72% premium that delivers immediate, certain value to public shareholders. Avanos Stock Surged on $1.27 Billion AIP Buyout Deal at 72% Premium</li>
<li>Positive Sentiment: Operational signal: Avanos reported a Q4 beat (EPS $0.29 vs. $0.24 est.; revenue topped estimates) and retains institutional holders, which supports the narrative that the business has improving fundamentals behind the strategic transaction. Avanos Medical Posts Q4 Beat as Institutional Investors Like Armistice Capital Hold Positions in Non-Opioid Pain Device Segment</li>
<li>Neutral Sentiment: Market coverage: Media outlets tracked the stock’s historic intraday surge and summarized deal terms and timing; this is informational but doesn’t change deal economics. AVNS stock records historic intraday surge – everything to know about the buyout deal by American Industrial Partners</li>
<li>Negative Sentiment: Legal/closing risk: Multiple shareholder-law firms have launched investigations and alerts alleging potential unfair price or fiduciary breaches related to the sale; litigation or a challenge could delay closing, increase costs or pressure the board to seek a higher bid. $HAREHOLDER ALERT: The M-A Class Action Firm Announces An Investigation of Avanos Medical, Inc. NYSE: AVNS</li>
</ul>
<div class="lb-trans"><ul>
<li>積極情緒：交易：Avanos 同意以每股 25.00 美元的現金被美國工業合作伙伴的附屬公司收購，估值約為 12.7 億美元——這是一項約 72% 的溢價，為公眾股東提供了即時且確定的價值。Avanos 股票因 12.7 億美元的 AIP 收購交易而大幅上漲，溢價 72%。</li>
<li>積極情緒：運營信號：Avanos 報告第四季度業績超出預期（每股收益 0.29 美元，預期 0.24 美元；收入超出預期），並保留機構持有者，這支持了業務在戰略交易背後基本面改善的敍述。Avanos Medical 發佈第四季度業績超出預期，機構投資者如 Armistice Capital 在非阿片類止痛設備領域持有頭寸。</li>
<li>中性情緒：市場覆蓋：媒體跟蹤了該股票歷史性的日內飆升，並總結了交易條款和時機；這只是信息性內容，但並未改變交易經濟。AVNS 股票記錄歷史性日內飆升——關於美國工業合作伙伴的收購交易你需要知道的一切。</li>
<li>消極情緒：法律/關閉風險：多家股東律師事務所已啓動調查和警報，聲稱與此次出售相關的潛在不公平價格或信託責任違反；訴訟或挑戰可能會延遲交易完成，增加成本或施壓董事會尋求更高的出價。$HAREHOLDER ALERT: M-A 集體訴訟事務所宣佈對 Avanos Medical, Inc.（紐約證券交易所代碼：AVNS）進行調查。</li>
</ul>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>Several research analysts recently weighed in on the stock. Zacks Research upgraded shares of Avanos Medical from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research report on Monday, January 26th. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Avanos Medical in a research report on Monday, December 22nd. Finally, Wall Street Zen upgraded shares of Avanos Medical from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Saturday, March 28th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of &#34;Reduce&#34;.</p>
<div class="lb-trans"><p>幾位研究分析師最近對該股票發表了看法。Zacks Research 在 1 月 26 日的研究報告中將 Avanos Medical 的股票評級從 “強烈賣出” 上調至 “持有”。Weiss Ratings 在 12 月 22 日的研究報告中重申了對 Avanos Medical 股票的 “賣出（d-）” 評級。最後，Wall Street Zen 在 3 月 28 日的研究報告中將 Avanos Medical 的股票評級從 “持有” 上調至 “買入”。一位研究分析師對該股票給予了 “持有” 評級，另一位則給予了 “賣出” 評級。根據 MarketBeat，該公司的共識評級為 “減持”。</p>
</div><p><strong>Get Our Latest Stock Report on AVNS</strong></p>
<div class="lb-trans"><p><strong>獲取我們最新的 AVNS 股票報告</strong></p>
</div><h2>Avanos Medical Stock Performance</h2>
<div class="lb-trans"><h2>Avanos Medical 股票表現</h2>
</div><p>The company has a quick ratio of 1.26, a current ratio of 2.15 and a debt-to-equity ratio of 0.12. The company's 50-day moving average is $14.27 and its two-hundred day moving average is $12.61. The company has a market capitalization of $1.14 billion, a P/E ratio of -15.58 and a beta of 1.05.</p>
<div class="lb-trans"><p>該公司的速動比率為 1.26，流動比率為 2.15，債務與股本比率為 0.12。該公司的 50 日移動平均線為 14.27 美元，200 日移動平均線為 12.61 美元。該公司的市值為 11.4 億美元，市盈率為-15.58，貝塔值為 1.05。</p>
</div><p>Avanos Medical (NYSE:AVNS - Get Free Report) last posted its quarterly earnings data on Tuesday, February 24th. The company reported $0.29 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.05. Avanos Medical had a negative net margin of 10.40% and a positive return on equity of 5.47%. The company had revenue of $180.90 million for the quarter, compared to analysts' expectations of $174.70 million. During the same period in the prior year, the business earned $0.43 earnings per share. Avanos Medical's revenue for the quarter was up .7% compared to the same quarter last year. Avanos Medical has set its FY 2026 guidance at 0.900-1.100 EPS. Equities analysts anticipate that Avanos Medical, Inc. will post 1.32 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Avanos Medical（紐約證券交易所代碼：AVNS - 獲取免費報告）最後一次發佈季度財報是在 2 月 24 日。該公司報告第四季度每股收益為 0.29 美元，超出共識預期的 0.24 美元，超出 0.05 美元。Avanos Medical 的淨利潤率為-10.40%，股本回報率為 5.47%。該公司第四季度的收入為 1.809 億美元，超過分析師預期的 1.747 億美元。在去年同期，該公司每股收益為 0.43 美元。Avanos Medical 本季度的收入較去年同期增長了 0.7%。Avanos Medical 已將 2026 財年的指導目標設定為每股收益 0.900-1.100。股票分析師預計 Avanos Medical, Inc. 本財年將發佈每股收益 1.32 美元。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>A number of institutional investors and hedge funds have recently bought and sold shares of AVNS. AQR Capital Management LLC grew its position in Avanos Medical by 46.4% during the first quarter. AQR Capital Management LLC now owns 192,864 shares of the company's stock valued at $2,700,000 after acquiring an additional 61,095 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Avanos Medical by 4.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,955 shares of the company's stock valued at $386,000 after acquiring an additional 1,121 shares during the last quarter. Millennium Management LLC grew its position in Avanos Medical by 508.3% during the first quarter. Millennium Management LLC now owns 547,740 shares of the company's stock valued at $7,849,000 after acquiring an additional 457,703 shares during the last quarter. Empowered Funds LLC grew its position in Avanos Medical by 5.4% during the first quarter. Empowered Funds LLC now owns 162,182 shares of the company's stock valued at $2,324,000 after acquiring an additional 8,348 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Avanos Medical by 17.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 140,810 shares of the company's stock valued at $2,018,000 after acquiring an additional 20,541 shares during the last quarter. 95.17% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>一些機構投資者和對沖基金最近買入和賣出了 AVNS 的股票。AQR Capital Management LLC 在第一季度將其在 Avanos Medical 的持倉增加了 46.4%。AQR Capital Management LLC 目前擁有 192,864 股該公司的股票，價值 2,700,000 美元，此前在上個季度增持了 61,095 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第一季度將其在 Avanos Medical 的持倉增加了 4.3%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 目前擁有 26,955 股該公司的股票，價值 386,000 美元，此前在上個季度增持了 1,121 股。Millennium Management LLC 在第一季度將其在 Avanos Medical 的持倉增加了 508.3%。Millennium Management LLC 目前擁有 547,740 股該公司的股票，價值 7,849,000 美元，此前在上個季度增持了 457,703 股。Empowered Funds LLC 在第一季度將其在 Avanos Medical 的持倉增加了 5.4%。Empowered Funds LLC 目前擁有 162,182 股該公司的股票，價值 2,324,000 美元，此前在上個季度增持了 8,348 股。最後，UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC 在第一季度將其在 Avanos Medical 的持倉增加了 17.1%。UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC 目前擁有 140,810 股該公司的股票，價值 2,018,000 美元，此前在上個季度增持了 20,541 股。95.17% 的股票目前由機構投資者持有。</p>
</div><h2>Avanos Medical Company Profile</h2>
<div class="lb-trans"><h2>Avanos Medical 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company's products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.</p>
<div class="lb-trans"><p>Avanos Medical 是一家全球醫療技術公司，開發和銷售廣泛的醫療設備組合，旨在改善醫院、門診和後期護理環境中的患者結果。該公司的產品專注於三個核心治療領域——疼痛管理、腸內餵養和呼吸護理——旨在幫助臨牀醫生管理術後疼痛、提供營養支持並協助各種急性和慢性病症患者的呼吸。</p>
</div><p>In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.</p>
<div class="lb-trans"><p>在疼痛管理領域，Avanos 提供非阿片類藥物輸送系統和冷凍鎮痛設備，包括可移動輸液泵和冷卻射頻消融平台。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Avanos Medical</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們認為比 Avanos Medical 更好的股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Avanos Medical Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Avanos Medical 嗎？</h2>
</div><p>Before you consider Avanos Medical, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Avanos Medical 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avanos Medical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Avanos Medical 並不在名單上。</p>
</div><p>While Avanos Medical currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Avanos Medical 目前在分析師中被評為減持，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Avanos Medical（NYSE:AVNS）交易量強勁 - 事情是這樣的